A Registry of Patients With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

- Patients able to give written informed consent
- Patients at least 18 years of age at time of informed consent signature
- Confirmed diagnosis of chronic moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's clinical judgment at the time of recruitment.
- Patients initiating a treatment for psoriasis as per regional policy. This will include secukinumab, other biologics, systemic treatments, and phototherapy. Decision to treat with any of the above-mentioned treatments must have been reached prior to and independently of recruitment in the study.
- Treatments prescribed in accordance to the product monograph and regional regulatory and reimbursement policies
- Patients able to understand and communicate with the investigator and comply with the requirements of the study.

Exclusion Criteria:

- Unwillingness or inability to comply with the study requirements
- Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days.